The Pink Sheet: Biopharma COVID-19 Collaborations May Avoid Antitrust Hurdles, FTC And DOJ Suggest

March 30, 2020

O’Melveny partner Ben Bradshaw, who co-chairs the firm’s Antitrust and Competition Practice, was quoted in this article discussing how the FTC and DOJ intend to help facilitate critical biopharma collaborations during the COVID-19 pandemic.

“As biopharma companies begin collaborating on development of treatments for COVID19, the US Federal Trade Commission and Department of Justice offer assurance that they will get speedy answers to any antitrust questions,” the article noted.

“It indicates that the agencies want to provide businesses with predictability and confidence and security as they are figuring out how to provide products and services to the market,” Bradshaw told the publication. “By the same token they are sending a clear signal this is not a blank check to engage in activity that is historically problematic, such as price fixing and market allocation.”

The Pink Sheet subscribers can access the full article here.